Beqalzi is a drug owned by Beone Medicines Usa Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 29, 2039. Details of Beqalzi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11420968 | Bcl-2 Inhibitors |
Apr, 2039
(12 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Beqalzi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Beqalzi's family patents as well as insights into
ongoing legal events
on those patents.
Beqalzi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Beqalzi's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 29, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Beqalzi Generics:
There are no approved generic versions for Beqalzi as of now.
About Beqalzi
Beqalzi is a drug owned by Beone Medicines Usa Inc. Beqalzi uses Sonrotoclax as an active ingredient. Beqalzi was launched by Beone Medicines in 2026.
Approval Date:
Beqalzi was approved by FDA for market use on 13 May, 2026.
Active Ingredient:
Beqalzi uses Sonrotoclax as the active ingredient. Check out other Drugs and Companies using Sonrotoclax ingredient
Dosage:
Beqalzi is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG | TABLET | Prescription | ORAL |
| 5MG | TABLET | Prescription | ORAL |
| 20MG | TABLET | Prescription | ORAL |
| 1MG | TABLET | Prescription | ORAL |